Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

TNM002 Injection is a recombinant fully human native monoclonal antibody (mAb) against tetanus toxin and is currently under development for indication of prophylaxis against tetanus.

Inclusion Criteria:Chinese male or female adults aged ≥ 18 years;Participants with dirty or contaminated wounds caused by various injury who require passive immunization as prophylaxis against tetanus;Participants who provide signed written informed consent form.Exclusion Criteria:Known or suspected allergy to the investigational product or its excipients, or have a history of allergy to human immunoglobulin products or other therapeutic monoclonal immunoglobulins;Suspect or diagnosed as tetanus;Prior vaccination history of ≥ 3 doses of tetanus toxoid or tetanus toxoid- containing vaccine;Any clinically significant chronic or acute medical condition that makes the subject unsuitable for participation;Current alcohol abuse, drug abuse or drug addictionOther protocol defined Inclusion/Exclusion criteria may apply